By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Alnylam Pharmaceuticals, Inc. officers and board members have only been selling lately: eight insiders unloaded about $44 million of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
ALNY also shows up in congressional disclosures: 2 reported trades from two lawmakers in two years. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters. This quarter so far: net selling. On the institutional side, 788 funds reported holding ALNY at the end of Q2 2026, and funds were split between buying and selling.
Are insiders buying or selling ALNY stock?
In the last 12 months Alnylam Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $44 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ALNY?
The most recent open-market insider trade in ALNY was filed on 2026-10-06.
How many institutions own ALNY?
788 investment managers reported holding ALNY in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ALNY?
Yes. Members of Congress reported 2 trades in ALNY over the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).